Medtech stories we missed this week: Nov. 17, 2017

Share

missed medtech

[Image from unsplash.com]

From Skyline Medical’s joint venture to Lensar receiving FDA clearance and CE Mark, here are seven medtech stories we missed this week but thought were still worth mentioning.

1. Skyline Medical launches JV deal with Helomics

Skyline Medical announced in a Nov. 15 press release that it has signed a joint venture agreement with Helomics. The agreement comes after a strategic collaboration between the companies that allows Skyline to reach more markets. The joint venture leverages the Helomics D-Chip platform to develop and market new approaches for personalized cancer diagnostics and care.

2. iReliev launches wearable arthritis-treatment EMS/Tens patch

iReliev recently introduced its PlayMakar Wireless EMS + TENS Unit that helps treat chronic pain from arthritis on the go, according to a Nov. 15 press release. The device features two functions that include transcutaneous electrical nerve stimulation (TENS) and electrical muscle stimulation (EMS). TENS helps block pain signals from the brain to provide pain relief while EMS stimulates muscles for conditions, strengthening and recovery using gentle electrical impulses. It has two rechargeable receivers that connect to electrode pads to allow for it to work wirelessly. The device has 14 preset therapy mode for personalized treatment and additional receivers can be added on for treating bigger areas.

3. Mortise Medical gets FDA clearance

Mortise Medical announced in a Nov. 14 press release that it has received FDA 510(k) clearance for its SyndesMetrics Syndesmosis Repair System. The system addresses clinical needs for syndesmotic disruption injuries like predictable and repeatable anatomic reduction, restoration of physiological motion and restoration of ankle stability. The SyndesMetrics implant system has minimal hardware prominence, no suture prominence and a reversible locking mechanism that secures high strength suture that that connects tibial and fibular implant components.

Get the full story on our sister site, MassDevice.

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.


Register now with the code "TAVR" and save 15% today.

Speak Your Mind

*